Black Rock Inc. Arcus Biosciences, Inc. Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
A detailed history of Black Rock Inc. transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 9,763,113 shares of RCUS stock, worth $197 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,763,113
              Previous 9,900,341
              
        
           1.39%
        
      
          
        Holding current value
$197 Million
            Previous $187 Million
            
        
           20.45%
        
      
          
        % of portfolio
0.0%
            Previous 0.0%
          
        Shares
	  13 transactions
	
  Others Institutions Holding RCUS
# of Institutions
211Shares Held
67MCall Options Held
3.18MPut Options Held
167K- 
    
      Vanguard Group Inc Valley Forge, PA6.56MShares$132 Million0.0% of portfolio
- 
    
      Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.97MShares$120 Million0.11% of portfolio
- 
    
      Woodline Partners LP San Francisco, CA4MShares$80.8 Million0.19% of portfolio
- 
    
      Suvretta Capital Management, LLC New York, NY3.69MShares$74.5 Million1.03% of portfolio
- 
    
      State Street Corp Boston, MA3.63MShares$73.3 Million0.0% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $1.46B
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...